| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JNCI/90.16.1205 |
| P698 | PubMed publication ID | 9719081 |
| P50 | author | Hyman B Muss | Q104758257 |
| Constance T Cirrincione | Q114373346 | ||
| P2093 | author name string | M R Green | |
| L Norton | |||
| D A Berry | |||
| D R Budman | |||
| R B Weiss | |||
| E Frei | |||
| W C Wood | |||
| I C Henderson | |||
| C R Ferree | |||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1205-1211 | |
| P577 | publication date | 1998-08-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B | |
| P478 | volume | 90 |
| Q53513591 | 20th-century advances in drug therapy in oncology--Part I. |
| Q40623460 | A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer. |
| Q33900921 | A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care |
| Q30430866 | A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study |
| Q36617051 | A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer |
| Q44048667 | A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002. |
| Q50990877 | A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. |
| Q51425302 | A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer. |
| Q53576374 | Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. |
| Q34032840 | Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms |
| Q34858284 | Adjuvant chemotherapy in older women with early-stage breast cancer |
| Q33873099 | Adjuvant systemic management of early stage carcinoma of the breast |
| Q35951346 | Advances in breast cancer: pathways to personalized medicine |
| Q37594895 | Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. |
| Q43661609 | Are medical oncologists biased in their treatment of the large woman with breast cancer? |
| Q33877899 | Assessment of HER2 status in breast cancer: why, when and how? |
| Q34134997 | Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). |
| Q38636006 | Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer |
| Q35799944 | Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey |
| Q38405004 | Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia |
| Q35601624 | Best use of adjuvant systemic therapies II, chemotherapy aspects: dose of chemotherapy-cytotoxicity, duration and responsiveness |
| Q35873283 | Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy |
| Q34713718 | Biobehavioral outcomes following psychological interventions for cancer patients |
| Q35129681 | Biphenotypic acute leukemia following intensive adjuvant chemotherapy for breast cancer: case report and review of the literature |
| Q64268770 | CYP2J27 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients |
| Q36485208 | Canadian supportive care recommendations for the management of neutropenia in patients with cancer |
| Q33332252 | Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer |
| Q33984071 | Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. |
| Q38121735 | Chemotherapy dosing in overweight and obese patients with cancer |
| Q37477083 | Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey |
| Q35107358 | Chemotherapy in the Elderly: Supportive Measures for Chemotherapy-Induced Myelotoxicity |
| Q33384061 | Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2. |
| Q33975071 | Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management |
| Q36458767 | Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study |
| Q51953747 | Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. |
| Q93162455 | Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study |
| Q34459673 | Commentary: chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines |
| Q44230472 | Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia |
| Q38736432 | Comparison of toxicity profile and tolerability between two standard of care paclitaxel-based adjuvant chemotherapy regimens in breast cancer. |
| Q30662240 | Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data |
| Q35048758 | Considerations in the design and development of transport inhibitors as adjuncts to drug therapy |
| Q38156167 | Contribution of the Local RAS to Hematopoietic Function: A Novel Therapeutic Target |
| Q35019658 | Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. |
| Q33367026 | Current and future use of hematopoietic growth factors in cancer medicine |
| Q36535401 | Defining principles of combination drug mechanisms of action |
| Q42112541 | Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining |
| Q24240568 | Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy |
| Q24186051 | Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy |
| Q36610747 | Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis |
| Q33385774 | Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy |
| Q80809590 | Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy |
| Q34284284 | Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives |
| Q37118467 | Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide follow |
| Q44527927 | Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer |
| Q88963712 | Early breast cancer: why does obesity affect prognosis? |
| Q36292773 | Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer |
| Q34678777 | Early operable breast cancer |
| Q47288520 | Effect of Body Mass Index- and Actual Weight-Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer. |
| Q37303210 | Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model. |
| Q89552926 | Efficacy of Jackfruit365™ Green Jackfruit Flour Fortified Diet on Pegfilgrastim to Prevent Chemotherapy-Induced Leukopenia, Irrespective of Tumor Type or Drugs Used-A Retrospective Study |
| Q34601123 | Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer |
| Q34871753 | Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis |
| Q38676386 | FOLFOX chemotherapy can safely be given to neutropenic patients with early-stage colorectal cancer for higher dose intensity and fewer visits |
| Q34108152 | Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer |
| Q92385917 | Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study |
| Q24803202 | First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study |
| Q99623871 | Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study |
| Q38109529 | Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia |
| Q38459524 | HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide |
| Q35576343 | HER2 evaluation and its impact on breast cancer treatment decisions |
| Q37331912 | Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541. |
| Q34396531 | High incidence of microsatellite instability and loss of heterozygosity in three loci in breast cancer patients receiving chemotherapy: a prospective study |
| Q35623087 | High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer |
| Q35871127 | High-dose chemotherapy in breast cancer |
| Q40554971 | High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast can |
| Q24642872 | How to calculate the dose of chemotherapy |
| Q64059951 | Impact of Essential Medicine Stock Outs on Cancer Therapy Delivery in a Resource-Limited Setting |
| Q35602282 | Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I-II breast cancers |
| Q49720458 | Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative |
| Q37577685 | Impact of granulocyte colony-stimulating factors in metastatic colorectal cancer patients |
| Q35596990 | Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients |
| Q36769011 | Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy |
| Q40316147 | Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. |
| Q35614159 | Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma |
| Q64069775 | Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials |
| Q46662710 | Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. |
| Q44245118 | Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study |
| Q37657782 | Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. |
| Q60050114 | Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Adva |
| Q36952188 | Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy |
| Q34109991 | Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer |
| Q82714364 | Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting |
| Q34996295 | Modelling chemotherapy effects on granulopoiesis |
| Q24801341 | Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy? |
| Q33389472 | Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study |
| Q49937810 | NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim |
| Q35791695 | Neutropenia Prediction Based on First-Cycle Blood Counts Using a FOS-3NN Classifier |
| Q80900054 | Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study |
| Q83171914 | Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment |
| Q30621000 | New data on adjuvant therapy for breast cancer |
| Q38436984 | Obesity and breast cancer: not only a risk factor of the disease |
| Q33900910 | Optimising chemotherapy dose density and dose intensity. new strategies to improve outcomes in adjuvant therapy for breast cancer |
| Q42790354 | Optimizing dose-dense regimens for early-stage breast cancer |
| Q34571917 | Optimum anthracycline-based chemotherapy for early breast cancer |
| Q47691132 | Outcome of patients with metastatic breast carcinoma treated at a private medical oncology clinic |
| Q37703409 | Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study |
| Q35024477 | Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia |
| Q37241723 | Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study. |
| Q42670935 | Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass |
| Q30885642 | Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study |
| Q34880894 | Premenopausal breast cancer: chemotherapy and endocrine therapy |
| Q33395708 | Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer |
| Q44982608 | Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study |
| Q36740694 | RCT of a psychological intervention for patients with cancer: I. mechanisms of change |
| Q47580264 | Racial Disparity in the Dose and Dose Intensity of Breast Cancer Adjuvant Chemotherapy |
| Q57108049 | Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis |
| Q36614607 | Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer |
| Q39698919 | Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies |
| Q54231437 | Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. |
| Q33543823 | Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study |
| Q36918707 | Risk factors for hematological toxicity of chemotherapy for bone and soft tissue sarcoma |
| Q40351157 | Risk of mortality in patients with cancer who experience febrile neutropenia |
| Q34611337 | Risks and consequences of chemotherapy-induced neutropenia |
| Q45762363 | Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients |
| Q36300761 | Selection of adjuvant chemotherapy for treatment of node-positive breast cancer |
| Q40546057 | Sequential High-Dose Alkylating Therapy and Stem Cell Support for High-Risk Stage III Breast Cancer |
| Q34558257 | Standard medical treatment for early breast cancer |
| Q35080295 | Study of suboptimum treatment response: lessons from breast cancer |
| Q37702827 | Supportive care in hemato-oncology: a review in light of the latest guidelines |
| Q36529853 | Supportive therapy in medical therapy of head and neck tumors |
| Q50565674 | Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial. |
| Q47384977 | Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model |
| Q80937679 | The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies |
| Q37807323 | The Economics of the Hematopoietic Growth Factors |
| Q36615818 | The analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancer |
| Q98238180 | The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients |
| Q38469612 | The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients |
| Q40698264 | The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence |
| Q33900916 | The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? |
| Q35916166 | The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study |
| Q51689988 | The inverted pyramid of biomarker-driven trials. |
| Q42682705 | Tolerability of a rapid-escalation vinblastine-prednisolone protocol in dogs with mast cell tumours |
| Q37163481 | Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013 |
| Q35024456 | Treatment of breast cancer with chemotherapy in combination with filgrastim: approaches to improving therapeutic outcome |
| Q37171287 | Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897 |
| Q47177355 | Tumor size, axillary lymph node status and steroid receptor expression in breast cancer: prognostic relevance 5 years after surgery |
| Q42017011 | Undertreatment of Cancer Patients With Chemotherapy Is a Global Concern |
| Q57126532 | Update on adjuvant chemotherapy for early breast cancer |
| Q43203198 | Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen |
| Q36095287 | Weight-based chemotherapy dosing in obese patients with cancer: back to the future |
| Q34558263 | What the clinician needs from the pathologist: evidence-based reporting in breast cancer |
| Q80130957 | [Dose intensity received in breast cancer treatment with chemotherapy] |
| Q35146274 | p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). |
Search more.